Erratum: Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010 (International Psychogeriatrics (2014) DOI: 10.1017/S1041610214001975);Trends in use of psychotropic medications among patients treated with cholinesterase inhibitors in Japan from 2002 to 2010

International Psychogeriatrics

Volumn 27, Issue 3, 2015, Pages 407-415

  Okumura, Yasuyuki ^a   Togo, Takashi ^b   Fujita, Junichi ^c  

^a Tokyu Toranomon Bldg   (Japan)

^b Inaho Clinic   (Japan)

^c KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

behavioral and psychological symptoms of dementia (BPSD); dementia; mental health policy; psychopharmacology

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; BROTIZOLAM; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; DONEPEZIL; ETIZOLAM; FLUVOXAMINE; HALOPERIDOL; HYPNOTIC SEDATIVE AGENT; LITHIUM; MIANSERIN; MILNACIPRAN; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRAZODONE; TRIAZOLAM; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; ZOLPIDEM; ZOPICLONE;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR DISORDER; BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS DEMENTIA; CROSS-SECTIONAL STUDY; DEMENTIA; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG UTILIZATION; FEMALE; GERIATRIC PATIENT; HEALTH SURVEY; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; OFF LABEL DRUG USE; OUTPATIENT; PRESCRIPTION; PREVALENCE; PSYCHOSIS; TREND STUDY; VERY ELDERLY; COMPLICATION; PSYCHOMOTOR AGITATION; PSYCHOPHARMACOLOGY;

AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; DEMENTIA; FEMALE; HUMANS; HYPNOTICS AND SEDATIVES; JAPAN; MALE; OFF-LABEL USE; PSYCHOMOTOR AGITATION; PSYCHOPHARMACOLOGY; PSYCHOTROPIC DRUGS;

EID: 84922266820     PISSN: 10416102     EISSN: 1741203X     Source Type: Journal    
DOI: 10.1017/S1041610214002294     Document Type: Erratum

References (36)

1. Agenzia Italiana del Farmaco (2005). Il Trattamento Farmacologico dei Disturbi Psicotici in Pazienti Affetti da Demenza. Available at: http://www.agenziafarmaco. gov.it/it/content/il-trattamento-farmacologico-dei-disturbi-psicotici-pazienti-affetti-da-demenza; last accessed 12 May 2014.
2. Banerjee, S. (2009). The Use of Antipsychotic Medication for People with Dementia: Time for Action. London: Institute of Psychiatry, King's College London.
3. Carrasco-Garrido, P., Lopez de Andres, A., Hernandez Barrera, V., Jimenez-Trujillo, I. and Jimenez-Garcia, R. (2013). National trends (2003-2009) and factors related to psychotropic medication use in community-dwelling elderly population. International Psychogeriatrics, 25, 328-338.
4. Cipriani, A. et al. (2009). Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet, 373, 746-758.
5. Declercq, T. et al. (2013). Withdrawal versus continuation of chronic antipsychotic drugs for behavioral and psychological symptoms in older people with dementia. Cochrane Database of Systematic Reviews, 3, CD007726.
6. Franchi, C. et al. (2012). Changes in trend of antipsychotics prescription in patients treated with cholinesterase inhibitors after warnings from Italian medicines agency: results from the EPIFARM-elderly project. European Neuropsychopharmacology, 22, 569-577.
7. Gallini, A., Andrieu, S., Donohue, J. M., Oumouhou, N., Lapeyre-Mestre, M. and Gardette, V. (2014). Trends in use of antipsychotics in elderly patients with dementia: impact of national safety warnings. European Neuropsychopharmacology, 24, 95-104.
8. Gareri, P., De Fazio, P., Manfredi, V. G. and De Sarro, G. (2014). Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. Journal of Clinical Psychopharmacology, 34, 109-123.
9. Gill, S. S. et al. (2007). Antipsychotic drug use and mortality in older adults with dementia. Annals of Internal Medicine, 146, 775-786.
10. Herrmann, N., Lanctot, K. L. and Hogan, D. B. (2013). Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian consensus conference on the diagnosis and treatment of dementia 2012. Alzheimer's Research and Therapy, 5, S5.
11. Hoffmann, F. (2013). Perceptions of German GPs on benefits and risks of benzodiazepines and Z-drugs. Swiss Medical Weekly, 143, w13745.
12. Kales, H. C. et al. (2011). Trends in antipsychotic use in dementia 1999-2007. Archives of General Psychiatry, 68, 190-197.
13. Levy, H. B. (2014). Non-benzodiazepine hypnotics and older adults: what are we learning about zolpidem? Expert Review of Clinical Pharmacology, 7, 5-8.
14. Lyketsos, C. G., Lopez, O., Jones, B., Fitzpatrick, A. L., Breitner, J. and DeKosky, S. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Journal of the American Medical Association, 288, 1475-1483.
15. Maglione, M. et al. (2011). Off-Label Use of Atypical Antipsychotics: an Update. Rockville, MD: AHRQ Publication.
16. Martinez, C., Jones, R. W. and Rietbrock, S. (2013). Trends in the prevalence of antipsychotic drug use among patients with Alzheimer's disease and other dementias including those treated with antidementia drugs in the community in the UK: a cohort study. BMJ Open, 3, e002080.
17. McCleery, J., Cohen, D. A. and Sharpley, A. L. (2014). Pharmacotherapies for sleep disturbances in Alzheimer's disease. Cochrane Database of Systematic Reviews, 3, CD009178.
18. Medicines and Healthcare Products Regulatory Agency (2009). Antipsychotics: use in elderly people with dementia. Drug Safety Update, 1, 5.
19. Mizushima, Y. (2002). Todays Drug Therapy in 2002. Tokyo: Nankodo.
20. Nakanishi, M., Hattori, K., Nakashima, T. and Sawamura, K. (2012). Priority for elderly persons with behavioral and psychological symptoms of dementia on waiting lists for placement in nursing homes in Japan: do nursing homes change priorities based on their own guidelines? Journal of the American Medical Directors Association, 13, 794-799.
21. National Institute for Health and Clinical Excellence (2006). Dementia: Supporting People with Dementia and their Carers in Health and Social Care. Manchester: National Institute for Health and Clinical Excellence.
22. National Institute of Population and Social Security Research (2014). Social Security in Japan. Available at: http://www.fda.gov/Drugs/DrugSafety/
23. PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm; last accessed 16 August 2014.
24. Rabins, P. V. et al. (2007). American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. American Journal of Psychiatry, 164, 5-56.
25. Richter, T., Meyer, G., Mohler, R. and Kopke, S. (2012). Psychosocial interventions for reducing antipsychotic medication in care home residents. Cochrane Database of Systematic Reviews, 12, CD008634.
26. Ruths, S. et al. (2013). Trends in psychotropic drug prescribing in Norwegian nursing homes from 1997 to 2009: a comparison of six cohorts. International Journal of Geriatric Psychiatry, 28, 868-876.
27. Schneider, L. S., Dagerman, K. S. and Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 294, 1934-1943.
28. Schulze, J., van den Bussche, H., Glaeske, G., Kaduszkiewicz, H., Wiese, B. and Hoffmann, F. (2013). Impact of safety warnings on antipsychotic prescriptions in dementia: nothing has changed but the years and the substances. European Neuropsychopharmacology, 23, 1034-1042.
29. Seitz, D. P., Adunuri, N., Gill, S. S., Gruneir, A., Herrmann, N. and Rochon, P. (2011). Antidepressants for agitation and psychosis in dementia. Cochrane Database of Systematic Reviews, CD008191.
30. Statistics and Information Department, Minister's Secretariat, Ministry of Health, Labor and Welfare (2011). Survey of Medical Care Activities in Public Health Insurance 2010. Tokyo: Japan: Health and Welfare Association.
31. Tampi, R. R. and Tampi, D. J. (2014). Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. American Journal of Alzheimer's Disease and Other Dementias. Epublished ahead of print.
32. Tannenbaum, C., Martin, P., Tamblyn, R., Benedetti, A. and Ahmed, S. (2014). Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the empower cluster randomized trial. Journal of the American Medical Association Internal Medicine, 174, 890-898.
33. U.S. Food and Drug Administration (2005). Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at: http://www.fda.gov/Drugs/DrugSafety/
34. PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicHealthAdvisories/ucm053171.htm; last accessed 5 May 2014.
35. U.S. Food and Drug Administration (2008). Information for Healthcare Professionals: Conventional Antipsychotics. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm; last accessed 5 May 2014.
36. Yeh, Y. C. and Ouyang, W. C. (2012). Mood stabilizers for the treatment of behavioral and psychological symptoms of dementia: an update review. Kaohsiung Journal of Medical Sciences, 28, 185-193.